Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s strategy
The drugmaker, best known for developing weight-loss and diabetes drugs, failed to excite investors hoping for a turnaround.
Source：MarketWatch
友情提醒：请广大读者理性看待市场信息，切实提高风险意识。站内所有内容仅系市场信息或相关方观点，不构成任何形式投资建议。